# MIDOS: A MICRORNA BIODOSIMETER

> **NIH NIH N01** · CHROMOLOGIC, LLC · 2023 · $1,599,007

## Abstract

ChromoLogic will team with the experienced groups at the University of Pittsburgh, Wake Forest University, Sarcoma Oncology and City of Hope Cancer Center, and Charles River-Laval to plan and carry out the studies. Specifically, the Contractor plans to validate ChromoLogic’s miRNA panel to predict neutropenia in the clinic (sarcoma patients), and obtain FDA approval (Phase 1); validate ChromoLogic’s miRNA panel to predict fibrosis in the clinic (head and neck cancer patients) and obtain FDA approval (Phase 1); and submit pre-EUA for panels to predict ARS (neutropenia) and DEARE (fibrosis) (Phase 2).

## Key facts

- **NIH application ID:** 10932599
- **Project number:** 75N93023C00016-0-9999-1
- **Recipient organization:** CHROMOLOGIC, LLC
- **Principal Investigator:** THERESA NGUYEN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $1,599,007
- **Award type:** —
- **Project period:** 2023-07-01 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10932599

## Citation

> US National Institutes of Health, RePORTER application 10932599, MIDOS: A MICRORNA BIODOSIMETER (75N93023C00016-0-9999-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10932599. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*